These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26686871)

  • 1. Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies.
    Trompet S; Postmus I; Slagboom PE; Heijmans BT; Smit RA; Maier AB; Buckley BM; Sattar N; Stott DJ; Ford I; Westendorp RG; de Craen AJ; Jukema JW
    Eur J Clin Pharmacol; 2016 Apr; 72(4):431-7. PubMed ID: 26686871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses.
    Trompet S; de Craen AJ; Postmus I; Ford I; Sattar N; Caslake M; Stott DJ; Buckley BM; Sacks F; Devlin JJ; Slagboom PE; Westendorp RG; Jukema JW;
    BMC Med Genet; 2011 Oct; 12():131. PubMed ID: 21977987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
    Postmus I; Johnson PC; Trompet S; de Craen AJ; Slagboom PE; Devlin JJ; Shiffman D; Sacks FM; Kearney PM; Stott DJ; Buckley BM; Sattar N; Ford I; Westendorp RG; Jukema JW
    Atherosclerosis; 2014 Jul; 235(1):58-64. PubMed ID: 24816038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Marian AJ
    Curr Atheroscler Rep; 2005 May; 7(3):177-8. PubMed ID: 15811249
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenomic importance of pravastatin.
    Peters B; Maitland-van der Zee AH
    Pharmacogenomics; 2008 Sep; 9(9):1207-10. PubMed ID: 18781848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.
    Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
    Atherosclerosis; 2012 Feb; 220(2):413-7. PubMed ID: 22189199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives.
    Postmus I; Verschuren JJ; de Craen AJ; Slagboom PE; Westendorp RG; Jukema JW; Trompet S
    Pharmacogenomics; 2012 May; 13(7):831-40. PubMed ID: 22594514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.
    Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
    Atherosclerosis; 2012 Feb; 220(2):456-62. PubMed ID: 22192511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
    Vassy JL; Gaziano JM; Green RC; Ferguson RE; Advani S; Miller SJ; Chun S; Hage AK; Seo SJ; Majahalme N; MacMullen L; Zimolzak AJ; Brunette CA
    JAMA Netw Open; 2020 Dec; 3(12):e2027092. PubMed ID: 33270123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.
    Peyser B; Perry EP; Singh K; Gill RD; Mehan MR; Haga SB; Musty MD; Milazzo NA; Savard D; Li YJ; Trujilio G; Voora D
    Circ Genom Precis Med; 2018 Sep; 11(9):e002228. PubMed ID: 30354330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke).
    Hosomi N; Kitagawa K; Nagai Y; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
    Stroke; 2018 Apr; 49(4):865-871. PubMed ID: 29511130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
    Albert MA; Danielson E; Rifai N; Ridker PM;
    JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.
    Akao H; Polisecki E; Schaefer EJ; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Packard C; Buckley BM; Kajinami K;
    Atherosclerosis; 2014 Jul; 235(1):176-81. PubMed ID: 24854628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atheroma progression in hyporesponders to statin therapy.
    Kataoka Y; St John J; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):990-5. PubMed ID: 25722430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.